Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., May 5, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that its Board of Directors will withdraw its proposal to shareholders for approval of the grant of discretionary authority to
ANN ARBOR, Mich., Apr 23, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) will host two one-hour telephone Question & Answer sessions to provide further clarity on the proposal to amend the Company's Restated Articles of Incorporation to position the
ANN ARBOR, Mich., Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the Company intends to seek shareholder approval to authorize the Board of Directors to amend Aastrom's Restated Articles
ANN ARBOR, Mich., Feb 15, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and Chief Financial Officer, has announced
ANN ARBOR, Mich., Jan 31, 2008 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Second Quarter Fiscal Year 2008 Investor Conference Call When: Friday, February 8, 2008 @ 9:00 am (Eastern) Where:
ANN ARBOR, Mich., Jan 17, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) ), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will participate in the Leerink Swann Novel Biologics Therapeutics
